Are GlaxoSmithKline's Do-Gooder Moves Genuine or Just Good PR?


He's young, charismatic, innovative and has got heart. At least that's the impression GlaxoSmithKline (GSK) CEO Andrew Witty gives to the outside world. His most recent initiative that's drawing attention? GSK is allowing free access to its library of 13,500 potential malaria treatments. Glaxo also intends to devote the profits from its experimental malaria vaccine to battling tropical illnesses in poor countries.